NEW YORK, August 11, 2015 /PRNewswire/ —
Equity Research Institute has initiated coverage on the following equities: Actinium Pharmaceuticals Inc. (AMEX: ATNM), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), BioDelivery Sciences International Inc. (NASDAQ: BDSI), iBio Inc. (AMEX: IBIO), and Lion Biotechnologies Inc. (NASDAQ: LBIO). Free research report on Actinium Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ATNM On Monday, August 10, 2015, the NASDAQ Composite ended at 5,101.80, up 1.15%, the Dow Jones Industrial Average advanced 1.39%, to finish the day at 17,615.17, and the S&P 500 closed at 2,104.18, up 1.28%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
Actinium Pharmaceuticals Inc.’s stock surged 8.59%, to close the day at $2.15. The stock recorded a trading volume of 5.67 million shares, much above its three months average volume of 1.28 million shares. Over the last one month and over the past three months, Actinium Pharmaceuticals Inc.’s shares have declined 10.79% and 19.48%, respectively. Furthermore, the stock has plummeted 63.50% since the start of this year. The company’s shares are trading 15.33% below their 50-day moving average. Additionally, Actinium Pharmaceuticals Inc. has a Relative Strength Index (RSI) of 47.07. Sign up and read the free notes on ATNM at:
On Monday, shares in Anthera Pharmaceuticals Inc. recorded a trading volume of 0.70 million shares, lower than their three months average volume of 1.26 million shares. The stock ended the day 2.51% higher at $9.80. Anthera Pharmaceuticals Inc.’s stock has rallied 17.72% in the last one month, 118.75% in the previous three months and 520.25% on YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.90% and 108.08%, respectively. Furthermore, shares of Anthera Pharmaceuticals Inc. have an RSI of 49.78. The complimentary notes on ANTH can be downloaded in PDF format at:
BioDelivery Sciences International Inc.’s stock gained 1.29%, to close Monday’s session at $7.05. The stock recorded a trading volume of 2.18 million shares, above its three months average volume of 1.25 million shares. Over the last one month and the previous three months, BioDelivery Sciences International Inc.’s shares have declined 18.40% and 7.72%, respectively. Additionally, the stock has lost 41.35% since the start of this year. The stock is trading 15.29% and 39.50% below its 50-day and 200-day moving averages, respectively. Furthermore, BioDelivery Sciences International Inc.’s stock has an RSI of 33.68. Register for free on Equity Research Institute and access the latest research on BDSI at:
iBio Inc.’s stock finished Monday’s session 3.36% lower at $0.62. A total of 0.69 million shares were traded, which was close to its three months average volume of 0.70 million shares. Over the last one month and the previous three months, iBio Inc.’s shares have plummeted 28.08%, each. Additionally, the stock has lost 9.71% since the beginning of 2015. The company’s shares are trading below their 50-day and 200-day moving averages by 28.19% and 26.54%, respectively. Further, iBio Inc.’s stock has an RSI of 30.79. The complete research on IBIO is available for free at:
On Monday, shares in Lion Biotechnologies Inc. ended the session 0.41% lower at $7.37. The stock reported a trading volume of 0.27 million shares, below its three months average volume of 0.69 million shares. Lion Biotechnologies Inc.’s shares have lost 19.19% in the last one month, 31.25% in the previous three months and 6.35% on YTD basis. The stock is trading 22.94% below its 50-day moving average and 19.56% below its 200-day moving average. Moreover, shares of Lion Biotechnologies Inc. have an RSI of 29.99. Free in-depth research on LBIO is available at:
About Equity Research Institute:
Equity Research Institute (“ERI”) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ERI has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). Rohit Tuli, a CFA® charter holder (the “CFA®”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ERI, the Author, the Reviewer and the CFA® (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.
ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.